Keywords: Bayer, Regorafenib, Onyx Pharma, Stromal tumors, GIST, USA, FDA

Bayer files NDA for regorafenib for the treatment of GIST

Article | 31 August 2012

Print This

The US subsidiary of Germany’s Bayer (BAYB: DE) has submitted a New Drug Application to the US Food ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in